Governance

ITI is governed by a nine-member Board of Directors, including one ex-officio member, the ITI President.

The ITI Board of Directors is committed to advancing the elimination of blinding trachoma through the work
of ITI and its partners worldwide.

Board of Directors

Robert L. Mallett
Chairman of ITI Board
Senior Vice President, Corporate Affairs, Pfizer Inc

H. Lawrence Clark
Secretary of ITI Board
Trustee, The Edna McConnell Clark Foundation

Michael A. Bailin
Former CEO and President, The Edna McConnell Clark Foundation

Patricia C. Barron
Chair, Ultralife Batteries Inc., and Corporate Director

C.L. Clemente
Executive Vice President, Corporate Affairs, Pfizer Inc (retired)

Joseph M. Feczko, M.D.
Senior Vice President, Chief Medical Officer, Pfizer Inc

Ibrahim Jabr
President, International Trachoma Initiative

Reatha Clark King, Ph.D.
Former President and Board Chair, General Mills Foundation

Alfred Sommer, M.D., M.H.S.
Dean Emeritus and Professor, Johns Hopkins Bloomberg School of Public Health

The International Trachoma Initiative (ITI) is dedicated to eliminating blinding trachoma, the world’s leading cause of preventable blindness.

ITI approaches its mission through targeted support—including Pfizer-donated Zithromax®—for expanded implementation of the SAFE Strategy, applied research and program evaluation, health education and advocacy.

Drawing on its unique role as a leader in catalyzing partnerships for trachoma control at the national and global levels, ITI will continue to seek out new approaches to expand SAFE programs and accelerate progress toward eliminating blinding trachoma.

ITI maintains the highest scientific and management standards in pursuit of its mission.